Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy - PubMed (original) (raw)
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy
T Kuukasjärvi et al. J Clin Oncol. 1996 Sep.
Abstract
Purpose: Up to 30% to 40% of metastases from hormone receptor-positive primary breast cancer do not respond to endocrine therapy. We studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy.
Patients and methods: Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy. Estrogen receptor (ER) and progesterone receptor (PR) status was determined immunohistochemically from histologically representative formalin-fixed paraffin-embedded tumor samples. ER status was ascertained by mRNA in situ hybridization.
Results: Thirty-five (70%) of 50 primary tumors were positive for ER and 30 (60%) for PR. Hormone receptor status of the recurrent tumor differed from that of the primary tumor in 18 cases (36%). Discordant cases were due to the loss of ER (n = 6), loss of PR (n = 6), or loss of both receptors (n = 6). Receptor-negative primary tumors were always accompanied by receptor-negative recurrences. Among 27 patients with ER-positive primary tumors, loss of ER was a significant predictor (P = .0085) of poor response to subsequent endocrine therapy. Only one of eight patients (12.5%) with lost ER expression responded to tamoxifen therapy, whereas the response rate was 74% (14 of 19) for patients whose recurrent tumors retained ER expression.
Conclusion: Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-positive patients. We conclude that analysis of recurrent tumor samples may improve the predictive value of ER and PR assays.
Comment in
- Breast cancer: relevance of estrogen receptor determination at relapse.
Spataro V, Goldhirsch A. Spataro V, et al. J Clin Oncol. 1997 Feb;15(2):862. J Clin Oncol. 1997. PMID: 9053515 No abstract available.
Similar articles
- Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE, Gough M, Middleton K, Hsieh M, Furnas L, Seidl B, Gibbons K, Pyke C, Shannon C, Woodward N, Armes JE. Snell CE, et al. J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17. J Clin Pathol. 2017. PMID: 28416639 - An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT. Henriksen KL, et al. Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383. Acta Oncol. 2009. PMID: 19173092 - The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY, Si W, Ji TF, Guo XQ, Hu Y, Yang JL. Zhu YY, et al. Tumour Biol. 2016 Jun;37(6):7675-84. doi: 10.1007/s13277-015-4649-7. Epub 2015 Dec 21. Tumour Biol. 2016. PMID: 26687919 - Factors predictive of response to hormone therapy in breast cancer.
Rastelli F, Crispino S. Rastelli F, et al. Tumori. 2008 May-Jun;94(3):370-83. doi: 10.1177/030089160809400314. Tumori. 2008. PMID: 18705406 Review. - Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.
Bense RD, Qiu SQ, de Vries EGE, Schröder CP, Fehrmann RSN. Bense RD, et al. Cancer Treat Rev. 2018 Nov;70:118-126. doi: 10.1016/j.ctrv.2018.07.015. Epub 2018 Jul 26. Cancer Treat Rev. 2018. PMID: 30149225 Review.
Cited by
- Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial-Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer.
Nair MG, Mavatkar AD, Naidu CM, V P S, C E A, Rajarajan S, Sahoo S, Mohan G, Jaikumar VS, Ramesh RS, B S S, Jolly MK, Maliekal TT, Prabhu JS. Nair MG, et al. Cells. 2024 May 10;13(10):821. doi: 10.3390/cells13100821. Cells. 2024. PMID: 38786043 Free PMC article. - The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases.
Liang XB, Dai ZC, Zou R, Tang JX, Yao CW. Liang XB, et al. Int J Mol Sci. 2023 Aug 31;24(17):13558. doi: 10.3390/ijms241713558. Int J Mol Sci. 2023. PMID: 37686364 Free PMC article. Review. - The epigenetic function of androgen receptor in prostate cancer progression.
Sawada T, Kanemoto Y, Kurokawa T, Kato S. Sawada T, et al. Front Cell Dev Biol. 2023 Mar 21;11:1083486. doi: 10.3389/fcell.2023.1083486. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37025180 Free PMC article. Review. - Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Haddad TC, et al. JAMA Oncol. 2023 Jun 1;9(6):815-824. doi: 10.1001/jamaoncol.2022.7949. JAMA Oncol. 2023. PMID: 36892847 Free PMC article. Clinical Trial. - Fine needle aspiration of pancreatic lesions focusing on secondary tumors with emphasis of metastatic breast cancer: A clinicopathological study with follow-up.
Chen MY, Zarrin-Khameh N, Xu Y. Chen MY, et al. Cancer Med. 2023 Mar;12(5):5485-5493. doi: 10.1002/cam4.5374. Epub 2022 Oct 24. Cancer Med. 2023. PMID: 36281523 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials